• Explore /
  • Poster
  • / Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.

Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.

Abstract Video & Slides Poster

Authors

Paula Rodríguez-Otero

Paula Rodríguez-Otero

Clinica Universidad De Navarra, Pamplona, Spain

Paula Rodríguez-Otero , Maria-Victoria Mateos , Albert Oriol , Alessandra Larocca , Joan Blade , Michele Cavo , Xavier Leleu , Omar Nadeem , John W. Hiemenz , Hani Hassoun , Cyrille Touzeau , Adrian Alegre , Agne Paner , Christopher Maisel , Amitabha Mazumder , Anastasios Raptis , Marcus Thuresson , Johan Harmenberg , Olof Harlin , Paul G. Richardson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02963493 and NCT01897714

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8048)

DOI

10.1200/JCO.2021.39.15_suppl.8048

Abstract #

8048

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Roman Hajek

First Author: Maria-Victoria Mateos

First Author: Sundar Jagannath

First Author: Allison Graeter